Clinical Trial Update: AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients [Phase 4]

View source ↗

Summary

This document reports the completion of the Phase 4 AML96 trial assessing risk-adapted postremission therapy for adult acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Snippet

Sponsor: Technische Universität Dresden | Conditions: Leukemia, Nonlymphoblastic, Acute | Phase 4 | Status: COMPLETED